| Year |
Citation |
Score |
| 2021 |
Hsiang M, Chobrutskiy BI, Diaz M, Huda TI, Creadore S, Zaman S, Cios KJ, Gozlan EC, Blanck G. Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates. Translational Oncology. 14: 101069. PMID 33780706 DOI: 10.1016/j.tranon.2021.101069 |
0.3 |
|
| 2020 |
Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology. PMID 32950267 DOI: 10.1016/J.Humimm.2020.08.007 |
0.367 |
|
| 2020 |
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment and Research Communications. 24: 100196. PMID 32769037 DOI: 10.1016/J.Ctarc.2020.100196 |
0.322 |
|
| 2020 |
Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology. PMID 32315578 DOI: 10.1089/Vim.2019.0156 |
0.338 |
|
| 2019 |
Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T-cell receptors and cancer-mutant amino acids: Multi-cancer analyses of associated survival rates. Immunology. PMID 31821535 DOI: 10.1111/Imm.13165 |
0.369 |
|
| 2019 |
Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene. PMID 31740784 DOI: 10.1038/S41388-019-1101-2 |
0.316 |
|
| 2019 |
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 31019293 DOI: 10.1038/S41374-019-0248-3 |
0.343 |
|
| 2019 |
Roca AM, Chobrutskiy BI, Callahan BM, Blanck G. T-cell receptor V and J usage paired with specific HLA alleles associates with distinct cervical cancer survival rates. Human Immunology. PMID 30684568 DOI: 10.1016/J.Humimm.2019.01.005 |
0.341 |
|
| 2019 |
Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low‑grade glioma. Oncology Reports. 41: 1359-1366. PMID 30535461 DOI: 10.3892/Or.2018.6896 |
0.333 |
|
| 2018 |
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal of Cancer Research and Clinical Oncology. PMID 30539280 DOI: 10.1007/S00432-018-2815-1 |
0.325 |
|
| 2018 |
Clark KR, Tong WL, Callahan BM, Yavorski JM, Tu YN, Blanck G. TRB-J1 usage, in combination with the HLA-A*01:01 allele, represents an apparent survival advantage for uterine corpus endometrial carcinoma: Comparisons with microscopic assessments of lymphocyte infiltrates. International Journal of Immunogenetics. PMID 30474304 DOI: 10.1111/Iji.12409 |
0.331 |
|
| 2018 |
Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle (Georgetown, Tex.). 1-10. PMID 30394813 DOI: 10.1080/15384101.2018.1542898 |
0.368 |
|
| 2018 |
Chobrutskiy BI, Zaman S, Tong WL, Diviney A, Blanck G. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. Journal of Neuro-Oncology. PMID 30382482 DOI: 10.1007/S11060-018-03001-1 |
0.311 |
|
| 2018 |
Fisler DA, Sikaria D, Yavorski JM, Tu YN, Blanck G. Elucidating feed-forward apoptosis signatures in breast cancer datasets: Higher FOS expression associated with a better outcome. Oncology Letters. 16: 2757-2763. PMID 30013671 DOI: 10.3892/Ol.2018.8957 |
0.351 |
|
| 2018 |
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Tong WL, Blanck G. Mutant cytoskeletal and ECM peptides sensitive to the ST14 protease are associated with a worse outcome for glioblastoma multiforme. Biochemical and Biophysical Research Communications. PMID 29953855 DOI: 10.1016/J.Bbrc.2018.06.141 |
0.39 |
|
| 2018 |
Callahan BM, Tong WL, Blanck G. T cell receptor-β J usage, in combination with particular HLA class II alleles, correlates with better cancer survival rates. Immunologic Research. PMID 29594966 DOI: 10.1007/S12026-018-8990-Y |
0.399 |
|
| 2018 |
Callahan BM, Yavorski JM, Tu YN, Tong WL, Kinskey JC, Clark KR, Fawcett TJ, Blanck G. T-cell receptor-β V and J usage, in combination with particular HLA class I and class II alleles, correlates with cancer survival patterns. Cancer Immunology, Immunotherapy : Cii. PMID 29508024 DOI: 10.1007/S00262-018-2139-7 |
0.431 |
|
| 2018 |
Kinskey JC, Tu YN, Tong WL, Yavorski JM, Blanck G. Recovery of Immunoglobulin VJ Recombinations from Pancreatic Cancer Exome Files Strongly Correlates with Reduced Survival. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. PMID 29404962 DOI: 10.1007/S12307-018-0205-5 |
0.315 |
|
| 2018 |
Mai AT, Tong WL, Tu YN, Blanck G. T-cell receptor-α recombinations in renal cell carcinoma exome files correlate with an intermediate level of T-cell exhaustion biomarkers. International Immunology. PMID 29361059 DOI: 10.1093/Intimm/Dxx074 |
0.327 |
|
| 2018 |
Tu YN, Tong WL, Yavorski JM, Blanck G. Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-γ/δ Recombinations. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. PMID 29357011 DOI: 10.1007/S12307-018-0204-6 |
0.325 |
|
| 2018 |
Sikaria D, Tu YN, Fisler DA, Mauro JA, Blanck G. Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology. PMID 29305708 DOI: 10.1007/S00432-017-2569-1 |
0.379 |
|
| 2018 |
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Blanck G. P081 ST14 protease resistant peptides, from glioblastoma multiforme mutant proteins, represent higher binding affinities as potential HLA class I epitopes Human Immunology. 79: 121. DOI: 10.1016/J.Humimm.2018.07.140 |
0.417 |
|
| 2017 |
Yavorski JM, Blanck G. MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development. Molecular and Clinical Oncology. 7: 1119-1121. PMID 29285385 DOI: 10.3892/Mco.2017.1432 |
0.47 |
|
| 2017 |
Callahan BM, Patel JS, Fawcett TJ, Blanck G. Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I, mutant epitope reservoir. International Journal of Cancer. PMID 29047110 DOI: 10.1002/Ijc.31111 |
0.387 |
|
| 2017 |
Tu YN, Tong WL, Fawcett TJ, Blanck G. Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28805806 DOI: 10.1038/Labinvest.2017.80 |
0.376 |
|
| 2017 |
Segarra DT, Yavorski JM, Blanck G. Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer. Biomedical Reports. 7: 163-168. PMID 28804630 DOI: 10.3892/Br.2017.940 |
0.346 |
|
| 2017 |
Uversky VN, Tu YN, Nwogu O, Butler SN, Ramsamooj M, Blanck G. High-level intrinsic disorder explains the universality of CLIP binding to diverse MHC class II variants. Cellular & Molecular Immunology. PMID 28757614 DOI: 10.1038/Cmi.2017.45 |
0.41 |
|
| 2017 |
Mauro JA, Yavorski JM, Blanck G. Stratifying melanoma and breast cancer TCGA datasets on the basis of the CNV of transcription factor binding sites common to proliferation- and apoptosis-effector genes. Gene. PMID 28257835 DOI: 10.1016/J.Gene.2017.02.026 |
0.416 |
|
| 2017 |
Tu YN, Tong WL, Samy MD, Yavorski JM, Kim M, Blanck G. Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-α/β V(D)J recombinations correlates with PD-1 expression. International Journal of Cancer. PMID 28256716 DOI: 10.1002/Ijc.30675 |
0.308 |
|
| 2017 |
Tong WL, Tu YN, Samy MD, Sexton WJ, Blanck G. Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Human Vaccines & Immunotherapeutics. 1-6. PMID 28085544 DOI: 10.1080/21645515.2016.1246095 |
0.367 |
|
| 2016 |
Samy MD, Tong WL, Yavorski JM, Sexton WJ, Blanck G. T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-β VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. Cancer Immunology, Immunotherapy : Cii. PMID 27995306 DOI: 10.1007/S00262-016-1943-1 |
0.346 |
|
| 2016 |
Sait S, Fawcett T, Blanck G. Overlap of the cancer genome atlas and the immune epitope database. Oncology Letters. 12: 2982-2984. PMID 27703532 DOI: 10.3892/Ol.2016.4991 |
0.323 |
|
| 2016 |
Yavorski JM, Blanck G. TCGA: Increased oncoprotein coding region mutations correlate with a greater expression of apoptosis-effector genes and a positive outcome for stomach adenocarcinoma. Cell Cycle (Georgetown, Tex.). 0. PMID 27355872 DOI: 10.1080/15384101.2016.1195532 |
0.35 |
|
| 2016 |
Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of Productively Rearranged TcR-α V-J Sequences in TCGA Exome Files: Implications for Tumor Immunoscoring and Recovery of Antitumor T-cells. Cancer Informatics. 15: 23-8. PMID 26966347 DOI: 10.4137/Cin.S35784 |
0.374 |
|
| 2016 |
Parry ML, Blanck G. Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Human Vaccines & Immunotherapeutics. 12: 120-3. PMID 26225584 DOI: 10.1080/21645515.2015.1073428 |
0.349 |
|
| 2015 |
Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, Szekeres K, Dana D, Kumar S, Ragupathi G, Blanck G. HLA-DR peptide occupancy can be regulated with a wide variety of small molecules. Human Vaccines & Immunotherapeutics. 0. PMID 26453454 DOI: 10.1080/21645515.2015.1089370 |
0.404 |
|
| 2015 |
Butler SN, Blanck G. Immunoscoring by correlating MHC class II and TCR expression: high level immune functions represented by the KIRP dataset of TCGA. Cell and Tissue Research. PMID 26293619 DOI: 10.1007/S00441-015-2261-1 |
0.512 |
|
| 2015 |
Garcia M, Mauro JA, Ramsamooj M, Blanck G. Tumor suppressor genes are larger than apoptosis-effector genes and have more regions of active chromatin: Connection to a stochastic paradigm for sequential gene expression programs. Cell Cycle (Georgetown, Tex.). 14: 2494-500. PMID 25945879 DOI: 10.1080/15384101.2015.1044179 |
0.418 |
|
| 2015 |
Lloyd MC, Szekeres K, Brown JS, Blanck G. Class II transactivator expression in melanoma cells facilitates T-cell engulfment. Anticancer Research. 35: 25-9. PMID 25550531 |
0.417 |
|
| 2015 |
Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells? Cancer Letters. 356: 479-82. PMID 25451318 DOI: 10.1016/J.Canlet.2014.09.044 |
0.369 |
|
| 2015 |
Mauro JA, Butler SN, Ramsamooj M, Blanck G. Copy number loss or silencing of apoptosis-effector genes in cancer. Gene. 554: 50-7. PMID 25307873 DOI: 10.1016/J.Gene.2014.10.021 |
0.387 |
|
| 2014 |
Szekeres K, Koul R, Mauro J, Lloyd M, Johnson J, Blanck G. An Oct-1-based, feed-forward mechanism of apoptosis inhibited by co-culture with Raji B-cells: towards a model of the cancer cell/B-cell microenvironment. Experimental and Molecular Pathology. 97: 585-9. PMID 25236570 DOI: 10.1016/J.Yexmp.2014.09.010 |
0.429 |
|
| 2014 |
Mauro JA, Blanck G. Functionally distinct gene classes as bigger or smaller transcription factor traps: a possible stochastic component to sequential gene expression programs in cancer. Gene. 536: 398-406. PMID 24291030 DOI: 10.1016/J.Gene.2013.11.013 |
0.408 |
|
| 2013 |
Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Human Vaccines & Immunotherapeutics. 9: 784-9. PMID 23328677 DOI: 10.4161/Hv.23085 |
0.471 |
|
| 2013 |
Pillai S, Szekeres K, Lawrence NJ, Chellappan SP, Blanck G. Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR. Gene. 512: 403-7. PMID 23041127 DOI: 10.1016/J.Gene.2012.09.092 |
0.573 |
|
| 2009 |
Narsing S, Jelsovsky Z, Mbah A, Blanck G. Genes that contribute to cancer fusion genes are large and evolutionarily conserved. Cancer Genetics and Cytogenetics. 191: 78-84. PMID 19446742 DOI: 10.1016/J.Cancergencyto.2009.02.004 |
0.306 |
|
| 2009 |
Coppola D, Parikh V, Boulware D, Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development Journal of Cancer Research and Clinical Oncology. 135: 1287-1291. PMID 19288270 DOI: 10.1007/S00432-009-0570-Z |
0.418 |
|
| 2009 |
Niesen MI, Osborne AR, Lagor WR, Zhang H, Kazemfar K, Ness GC, Blanck G. Technological advances in the study of HLA-DRA promoter regulation: extending the functions of CIITA, Oct-1, Rb, and RFX. Acta Biochimica Et Biophysica Sinica. 41: 198-205. PMID 19280058 DOI: 10.1093/Abbs/Gmp002 |
0.807 |
|
| 2009 |
Niesen MI, Blanck G. Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biological & Pharmaceutical Bulletin. 32: 480-2. PMID 19252299 DOI: 10.1248/Bpb.32.480 |
0.469 |
|
| 2009 |
Xu L, Niesen MI, Blanck G. Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Molecular Immunology. 46: 569-75. PMID 18952290 DOI: 10.1016/J.Molimm.2008.07.035 |
0.406 |
|
| 2008 |
Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. 1990. Journal of Immunology (Baltimore, Md. : 1950). 180: 2737-40. PMID 18292490 |
0.341 |
|
| 2006 |
Palubin KM, Goodwin BL, Niesen MI, Le EA, Osborne AR, Blanck G. A direct mechanistic link between growth control and a tumor cell immune function: increased interleukin-8 secretion accounts for elimination of Oct-1 antisense transformants from scid mice. Anticancer Research. 26: 1733-8. PMID 16827100 |
0.748 |
|
| 2006 |
Osborne AR, Zhang H, Blanck G. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line. Molecular Immunology. 43: 710-6. PMID 16360016 DOI: 10.1016/J.Molimm.2005.03.013 |
0.819 |
|
| 2005 |
Le E, Zhang H, Blanck G. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells. Anticancer Research. 25: 3889-92. PMID 16312044 |
0.608 |
|
| 2005 |
Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. The Journal of Biological Chemistry. 280: 38914-22. PMID 16166088 DOI: 10.1074/Jbc.M504633200 |
0.722 |
|
| 2004 |
Osborne AR, Zhang H, Fejer G, Palubin KM, Niesen MI, Blanck G. Oct-1 maintains an intermediate, stable state of HLA-DRA promoter repression in Rb-defective cells: an Oct-1-containing repressosome that prevents NF-Y binding to the HLA-DRA promoter. The Journal of Biological Chemistry. 279: 28911-9. PMID 15105429 DOI: 10.1074/Jbc.M403118200 |
0.811 |
|
| 2004 |
Blanck G. Mutations and regulatory anomalies effecting tumor cell immune functions. Cancer Immunology, Immunotherapy : Cii. 53: 1-16. PMID 13680191 DOI: 10.1007/S00262-003-0418-3 |
0.37 |
|
| 2003 |
Eason DD, LeBron C, Coppola D, Moscinski LC, Livingston S, Sutton ET, Blanck G. Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1. Oncogene. 22: 6166-76. PMID 13679855 DOI: 10.1038/Sj.Onc.1206563 |
0.732 |
|
| 2003 |
Xi H, Blanck G. The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1. Molecular Immunology. 39: 677-84. PMID 12493643 DOI: 10.1016/S0161-5890(02)00214-6 |
0.783 |
|
| 2001 |
Osborne A, Zhang H, Yang W, Seto E, Blanck G. Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase, I-hypersensitive chromatin conformation Molecular and Cellular Biology. 21: 6495-6506. PMID 11533238 DOI: 10.1128/Mcb.21.19.6495-6506.2001 |
0.824 |
|
| 2001 |
Eason DD, Coppola D, Livingston S, Shepherd AT, Blanck G. Loss of MHC class II inducibility in hyperplastic tissue in Rb-defective mice. Cancer Letters. 171: 209-14. PMID 11520605 DOI: 10.1016/S0304-3835(01)00603-6 |
0.81 |
|
| 2001 |
Xi H, Goodwin B, Shepherd AT, Blanck G. Impaired class II transactivator expression in mice lacking interferon regulatory factor-2. Oncogene. 20: 4219-27. PMID 11464288 DOI: 10.1038/Sj.Onc.1204556 |
0.795 |
|
| 2001 |
Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 12: 327-35. PMID 11432807 |
0.805 |
|
| 2001 |
Eason DD, Blanck G. High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway. Journal of Immunology (Baltimore, Md. : 1950). 166: 1041-8. PMID 11145683 DOI: 10.4049/Jimmunol.166.2.1041 |
0.804 |
|
| 2000 |
Zhang H, Wei S, Sun J, Coppola D, Zhong B, Wu GD, Goodwin B, Sebti S, Djeu JY, Blanck G. Retinoblastoma protein activation of interleukin 8 expression inhibits tumor cell survival in nude mice. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 11: 635-9. PMID 11149598 |
0.501 |
|
| 2000 |
Xi H, Blanck G. Interferon regulatory factor-2 point mutations in human pancreatic tumors. International Journal of Cancer. 87: 803-8. PMID 10956389 DOI: 10.1002/1097-0215(20000915)87:6<803::Aid-Ijc7>3.0.Co;2-E |
0.795 |
|
| 2000 |
Blanck G. HLA class II expression in human tumor lines. Microbes and Infection. 1: 913-8. PMID 10614009 DOI: 10.1016/S1286-4579(99)00226-9 |
0.472 |
|
| 1999 |
Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 18: 5889-903. PMID 10557076 DOI: 10.1038/Sj.Onc.1202969 |
0.808 |
|
| 1999 |
Zhang H, Shepherd AT, Eason DD, Wei S, Diaz JI, Djeu JY, Wu GD, Blanck G. Retinoblastoma protein expression leads to reduced Oct-1 DNA binding activity and enhances interleukin-8 expression. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 10: 457-65. PMID 10437913 |
0.835 |
|
| 1999 |
Eason DD, Shepherd AT, Blanck G. Interferon regulatory factor 1 tryptophan 11 to arginine point mutation abolishes DNA binding. Biochimica Et Biophysica Acta. 1446: 140-4. PMID 10395927 DOI: 10.1016/S0167-4781(99)00078-0 |
0.774 |
|
| 1998 |
Osborne A, Tschickardt M, Blanck G. Retinoblastoma protein expression facilitates chromatin remodeling at the HLA-DRA promoter. Nucleic Acids Research. 25: 5095-102. PMID 9396821 DOI: 10.1093/Nar/25.24.5095 |
0.798 |
|
| 1997 |
Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunology and Cell Biology. 75: 325-32. PMID 9315472 DOI: 10.1038/Icb.1997.50 |
0.546 |
|
| 1997 |
Schmidt B, Carter SS, Berry DE, Blanck G. Vitamin D3 reduces the apoptotic effect of IFN-gamma but does not facilitate HLA class II inducibility in RB-defective cells. Cancer Letters. 110: 169-76. PMID 9018097 DOI: 10.1016/S0304-3835(96)04487-4 |
0.518 |
|
| 1996 |
Lu Y, Schmidt B, Tschickardt M, Berry D, Blanck G. CIITA defects in human tumor lines Human Immunology. 47: 26. DOI: 10.1016/0198-8859(96)84819-1 |
0.303 |
|
| 1996 |
Lu Y, Boss JM, Hu S, Xu H, Blanck G. Retinoblastoma protein rescue of HLA class II mRNA IFN-γ inducibility in non-small cell lung carcinoma (NSCLC) cells Human Immunology. 47: 16. DOI: 10.1016/0198-8859(96)84761-6 |
0.43 |
|
| 1995 |
Lu Y, Ussery GD, Jacim M, Tschickardt M, Boss JM, Blanck G. Retinoblastoma protein regulation of surface CD74 (invariant chain) expression in breast carcinoma cells. Molecular Immunology. 31: 1365-8. PMID 7997248 DOI: 10.1016/0161-5890(94)90055-8 |
0.481 |
|
| 1995 |
Tschickardt ME, Lu Y, Jacim M, Ussery GD, Steimle V, Mach B, Blanck G. RB and a novel E2F-1 binding protein in MHC class II deficient B-cell lines and normal IFN-gamma induction of the class IL transactivator CIITA in class II non-inducible RB-defective tumor lines. International Journal of Cancer. 62: 461-5. PMID 7635572 DOI: 10.1002/Ijc.2910620417 |
0.557 |
|
| 1993 |
Lu Y, Ussery GD, Marler DF, Muncaster MM, Gallie BL, Blanck G. RETINOBLASTOMA PROTEIN REGULATION OF HLA CLASS II GENE EXPRESSION Journal of Immunotherapy. 14: 365. DOI: 10.1097/00002371-199311000-00047 |
0.493 |
|
| 1990 |
Blanck G, Strominger JL. Cosmid clones in the HLA-DZ and -DP subregions. Human Immunology. 27: 265-8. PMID 2341304 DOI: 10.1016/0198-8859(90)90056-U |
0.374 |
|
| 1990 |
Spies T, Bresnahan M, Bahrain S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway Nature. 348: 744-747. PMID 2259384 DOI: 10.1038/348744A0 |
0.433 |
|
| 1990 |
Blanck G, Lok M, Kok K, Downie E, Korn JH, Strominger JL. Gamma-interferon induction of HLA class II mRNAs in dermal fibroblasts studied by RNAse protection analysis. Human Immunology. 29: 150-6. PMID 2123483 DOI: 10.1016/0198-8859(90)90078-4 |
0.45 |
|
| 1989 |
Spies T, Blanck G, Bresnahan M, Sands J, Strominger JL. A new cluster of genes within the human major histocompatibility complex. Science (New York, N.Y.). 243: 214-7. PMID 2911734 DOI: 10.1126/Science.2911734 |
0.379 |
|
| 1985 |
Levitt A, Chen S, Blanck G, George D, Pollack RE. Two integrated partial repeats of simian virus 40 together code for a super-T antigen. Molecular and Cellular Biology. 5: 742-750. PMID 2985968 DOI: 10.1128/Mcb.5.4.742 |
0.313 |
|
| 1984 |
Chen S, Blanck G, Pollack R. Reacquisition of a functional early region by a mouse transformant containing only defective simian virus 40 DNA. Molecular and Cellular Biology. 4: 666-670. PMID 6325888 DOI: 10.1128/Mcb.4.4.666 |
0.315 |
|
| 1984 |
Blanck G, Chen S, Pollack R. DNase I sensitivity of integrated simian virus 40 DNA. Molecular and Cellular Biology. 4: 559-562. PMID 6325884 DOI: 10.1128/Mcb.4.3.559 |
0.312 |
|
| 1983 |
Lewis ED, Chen S, Kumar A, Blanck G, Pollack RE, Manley JL. A frameshift mutation affecting the carboxyl terminus of the simian virus 40 large tumor antigen results in a replication- and transformation-defective virus. Proceedings of the National Academy of Sciences of the United States of America. 80: 7065-9. PMID 6316342 DOI: 10.1073/Pnas.80.23.7065 |
0.372 |
|
| 1983 |
Blanck G, Chen S, Pollack R. Integration, loss, and reacquisition of defective viral DNA in SV40-transformed mouse cell lines. Virology. 126: 413-428. PMID 6304999 DOI: 10.1016/S0042-6822(83)80001-4 |
0.326 |
|
| Show low-probability matches. |